Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Jun 24, 2021 1:30pm
125 Views
Post# 33444684

RE:Shareholders' patience reserve" now very low...

RE:Shareholders' patience reserve" now very low...
Snowballgrowth wrote: We now have to see significant growth and higher margins ! .. and hope to get LATAM's currencies are going in the right direction vs Can $


Yes ...

growth will come from additional drugs added to the portfolio, jockeying exisiting drugs to new geographies and for new indications and improved marketing of existing drugs.

higher margins will come from changes in pricing strategy on certain drugs and reduced internal costs.

On the currency side, there will need to be some hedging but more importantly, you likely reinvest that depressed currency in opportunities of the same currency - to grow profits that can later be converted into higher Canadian dollars.  That's likely the slowest game but fits GUD's patient approach to investing.

just thinking out loud.
<< Previous
Bullboard Posts
Next >>